The Valley Desk

NCT01742988 · Interventional trial

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Overall registry status Completed

Phase 1

Conditions Double-expressor Lymphoma (DEL), Double-hit Lymphoma (DHL), High-grade B-cell Lymphoma (HGBL), Lymphoma, Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Lymphoma, Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL), Relapsed Lymphoma, Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed and/or Refractory Lymphoma, Triple-hit Lymphoma (THL)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov